| Literature DB >> 34934826 |
Akihiro Morita1, Yuta Omoya1, Rie Ito1, Yuya Ishibashi1, Keiichi Hiramoto1, Shiho Ohnishi1, Nobuji Yoshikawa2, Shosuke Kawanishi1.
Abstract
The acute liver disease is involved in aberrant release of high-mobility group box 1 (HMGB1). Glycyrrhizin (GL), a traditional Chinese medicine for liver disease, binds to HMGB1, thereby inhibits tissue injury. However the mode of action of GL for chronic liver disease remains unclear. We investigated the effects of glycyrrhizin (GL) and its derivatives on liver differentiation using human iPS cells by using a flow cytometric analysis. GL promoted hepatic differentiation at the hepatoblast formation stage. The GL derivatives, 3-O-mono-glucuronyl 18β-glycyrrhetinic acid (Mono) and 3-O-[glucosyl (1 → 2)-glucuronyl] 18β-glycyrrhetinic acid increased AFP+ cell counts and albumin+ cell counts. Glucuronate conjugation seemed to be a requirement for hepatic differentiation. Mono exhibited the most significant hepatic differentiation effect. We evaluated the effects of (±)-2-(2,4-dichlorophenoxy) propionic acid (DP), a T1R3 antagonist, and sucralose, a T1R3 agonist, on hepatic differentiation, and found that DP suppressed Mono-induced hepatic differentiation, while sucralose promoted hepatic differentiation. Thus, GL promoted hepatic differentiation via T1R3 signaling. In addition, Mono increased β-catenin+ cell count and decreased Hes5+ cell count suggesting the involvement of Wnt and Notch signaling in GL-induced hepatic differentiation. In conclusion, GL exerted a hepatic differentiation effect via sweet receptor (T1R3), canonical Wnt, and Notch signaling.Entities:
Keywords: AFP, α-fetoprotein; Api, 3-O-[apiosyl (1 → 2)-glucuronyl] βGA; CBX, carbenoxolone, 3-O-hemisuccinyl βGA; CK-19, cytokeratin 19; DMSO, dimethyl sulfoxide; DP, (±)-2-(2,4-dichlorophenoxy) propionic acid; GL, glycyrrhizin; Glc, 3-O-[glucosyl (1 → 2)-glucuronyl] βGA; Glycyrrhizin; HMGB1, high-mobility group box1; HNF-4α, hepatocyte nuclear factor 4α; Hepatic differentiation; Hes, hairy and enhancer of split; LSG, licorice saponin G; LSH, licorice saponin H; Liver regeneration; Mono, 3-O-mono-glucuronyl βGA; Sweet receptor; T1R3; αGA, 18α-glycyrrhetinic acid; βGA, 18β-glycyrrhetinic acid
Year: 2021 PMID: 34934826 PMCID: PMC8654616 DOI: 10.1016/j.bbrep.2021.101181
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1Effects of glycyrrhizin on hepatic differentiation of human iPS cells.
Hepatic induction of human iPS cells was performed according to the method described by Si-Tayeb et al. [18] with minor modification (A). After immunoreaction with anti-APF (B) and anti-albumin (C) antibodies, the cells were subjected to flow cytometric analysis. ** and *** indicate significant differences (p < 0.01 and 0.001, respectively) as determined by ANOVA followed by Tukey's post-hoc test (n = 3). DMSO: solvent control; GL: 1 μM glycyrrhizin treatment; (1): GL treatment throughout the hepatic differentiation; (2): GL treatment for the hepatoblast formation stage. Structure of glycyrrhizin and its derivatives (D). GL: glycyrrhizin; αGA: 18α-glycyrrhetinic acid; βGA: 18β-glycyrrhetinic acid; LSG: licorice saponin G; LSH: licorice saponin H; CBX: carbenoxolone, 3-O-hemisuccinyl βGA; Mono: 3-O-mono-glucuronyl βGA; Glc; 3-O-[glucosyl (1 → 2)-glucuronyl] βGA; Api: 3-O-[apiosyl (1 → 2)-glucuronyl] βGA.
Fig. 2Effect of glycyrrhizin and its derivatives on hepatic differentiation of human iPS cells.
Glycyrrhizin (GL), its derivatives (Api, Glc, Mono, CBX, αGA, βGA, LSG, and LSH), or the solvent control (Ctl) were administered to cells at the hepatoblast formation stage (on days 10–15). After immunoreaction with anti-APF (A), anti-albumin (B), and anti-CK-19 (C) antibodies, the cells were subjected to flow cytometric analysis. * and ** represent significant differences compared to Ctl (p < 0.025 and 0.005, respectively) as determined by Fisher's protected LSD (n = 3).
Fig. 3Effect of a sweet receptor agonist and antagonist on glycyrrhetinic acid mono glucuronide-induced hepatic differentiation of human iPS cells.
Hepatic induction of human iPS cells was performed. Mono and DP (T1R3 antagonist; A-C), sucralose (T1R3 agonist; D-F), or the solvent control (Ctl) was administered to the cells at the hepatoblast formation stage (on days 10–15). After immunoreaction with anti-APF (A, D), anti-albumin (B, E), and anti-CK-19 (C, F) antibodies, the cells were subjected to flow cytometric analysis. * and ** indicate significant differences (p < 0.025 and 0.005, respectively) as determined by Fisher's protected LSD (n = 3).
Fig. 4Effect of glycyrrhetinic acid mono glucuronide on Wnt and Notch signaling in hepatic differentiation of human iPS cells.
Mono or the solvent control (Ctl) was administered to the cells at the hepatoblast formation stage (on days 10–15). After immunoreaction with anti-β-catenin (A), anti-Numb (B), anti-Notch1 (C) and anti-Hes5 (D) antibodies, the cells were subjected to flow cytometric analysis. * indicates significant differences (p < 0.025) as determined by Fisher's protected LSD (n = 3–4). The GL signaling pathway during liver regeneration (E). [ATP]c: intracellular ATP concentration; Fz/LRP5/6: Frizzled/low-density lipoprotein receptor-related protein5/6; GSK3β: glycogen synthase kinase 3β.